UY34027A - Inhibidores sustituidos de acetil-coa carboxilasa. - Google Patents

Inhibidores sustituidos de acetil-coa carboxilasa.

Info

Publication number
UY34027A
UY34027A UY0001034027A UY34027A UY34027A UY 34027 A UY34027 A UY 34027A UY 0001034027 A UY0001034027 A UY 0001034027A UY 34027 A UY34027 A UY 34027A UY 34027 A UY34027 A UY 34027A
Authority
UY
Uruguay
Prior art keywords
carboxilasa
acetil
coa
inhibitors
replaced
Prior art date
Application number
UY0001034027A
Other languages
English (en)
Inventor
David Andrew Griffith
Robert Lee Dow
James Alfred Southers Jr
David James Edmonds
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY34027A publication Critical patent/UY34027A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Photographic Processing Devices Using Wet Methods (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención proporciona un compuesto de Fórmula (I) o una sal del mismo aceptable desde el punto de vista farmacéutico; donde G es R1, R2 y R3 son como se describe en la presente; composiciones farmacéuticas del mismo; y el uso del mismo en el trat amiento de enfermedades, afecciones o trastornos modulados por la inhibición de una enzima(s) acetil-CoA carboxilasa en un animal.
UY0001034027A 2011-04-22 2012-04-19 Inhibidores sustituidos de acetil-coa carboxilasa. UY34027A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161478240P 2011-04-22 2011-04-22

Publications (1)

Publication Number Publication Date
UY34027A true UY34027A (es) 2013-04-05

Family

ID=46025823

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034027A UY34027A (es) 2011-04-22 2012-04-19 Inhibidores sustituidos de acetil-coa carboxilasa.

Country Status (41)

Country Link
US (4) US8802688B2 (es)
EP (1) EP2699576B1 (es)
JP (1) JP5657174B2 (es)
KR (1) KR101567659B1 (es)
CN (2) CN106117205B (es)
AP (1) AP3499A (es)
AR (1) AR086198A1 (es)
AU (1) AU2012245996B2 (es)
CA (1) CA2831380C (es)
CL (1) CL2013002794A1 (es)
CO (1) CO6801757A2 (es)
CR (1) CR20130464A (es)
CU (1) CU24164B1 (es)
CY (1) CY1117122T1 (es)
DK (1) DK2699576T3 (es)
DO (1) DOP2013000243A (es)
EA (1) EA022375B1 (es)
EC (1) ECSP13013038A (es)
ES (1) ES2561452T3 (es)
GE (1) GEP20166474B (es)
GT (1) GT201300258A (es)
HR (1) HRP20151397T1 (es)
HU (1) HUE028602T2 (es)
IL (1) IL228949A (es)
MA (1) MA35061B1 (es)
ME (1) ME02312B (es)
MX (1) MX348860B (es)
MY (1) MY162167A (es)
NI (1) NI201300111A (es)
NZ (1) NZ616156A (es)
PE (1) PE20141187A1 (es)
PL (1) PL2699576T3 (es)
PT (1) PT2699576E (es)
RS (1) RS54526B1 (es)
SG (1) SG194142A1 (es)
SI (1) SI2699576T1 (es)
TN (1) TN2013000393A1 (es)
TW (1) TWI464171B (es)
UA (1) UA107753C2 (es)
UY (1) UY34027A (es)
WO (1) WO2012143813A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2499139E (pt) * 2009-11-10 2014-02-10 Pfizer Inibidores de n1-pirazolospirocetona acetil-coa carboxilase
CN102491974B (zh) * 2011-12-12 2013-08-07 南京药石药物研发有限公司 1-（2-氟苄基）-1H-吡唑并[3，4-b]吡啶-3-甲脒盐酸盐的合成方法
KR102243637B1 (ko) 2013-03-14 2021-04-26 리커리엄 아이피 홀딩스, 엘엘씨 바이사이클릭 진통 화합물
BR112015028152A2 (pt) 2013-05-10 2017-07-25 Nimbus Apollo Inc inibidores de acc e usos dos mesmos
WO2014182951A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
BR112015028171A8 (pt) * 2013-05-10 2017-08-22 Nimbus Apollo Inc Inibidores de acc e seu uso
CN105530940A (zh) * 2013-09-12 2016-04-27 辉瑞大药厂 乙酰辅酶a羧化酶抑制剂用于治疗寻常痤疮的用途
WO2015056782A1 (ja) 2013-10-17 2015-04-23 塩野義製薬株式会社 新規アルキレン誘導体
KR102380609B1 (ko) 2013-12-12 2022-03-30 리커리엄 아이피 홀딩스, 엘엘씨 바이사이클릭 알킬 화합물 및 합성
WO2015134710A1 (en) 2014-03-07 2015-09-11 Kalyra Pharmaceuticals, Inc. Propellane derivates and synthesis
CA2892342C (en) 2014-05-22 2016-11-01 Sylvain-Paul Morency Tool and method for layer depalletizing
EP3193855B1 (en) 2014-09-17 2021-05-19 Recurium IP Holdings, LLC Bicyclic compounds
KR102676056B1 (ko) * 2015-12-31 2024-06-19 베이징 구쉔 라이프 헬스 테크놀로지 컴퍼니 리미티드 비알코올성 지방간 질환의 치료 또는 예방용 의약의 제조에서의 트리아세틸-3-하이드록시페닐아데노신의 용도
CN106580986B (zh) * 2016-11-28 2017-09-15 王保亮 一种治疗少弱精子症的药物组合物
WO2018213140A1 (en) 2017-05-15 2018-11-22 Zeno Royalties & Milestones, LLC Analgesic compounds
CA3082867C (en) 2017-11-21 2022-05-10 Pfizer Inc. Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid
CN111574530B (zh) * 2020-04-21 2022-07-26 徐州医科大学 一种acc抑制剂及其医药用途
CN118271307A (zh) * 2022-12-30 2024-07-02 苏州浦合医药科技有限公司 Prmt5-mta抑制剂
WO2024213044A1 (en) * 2023-04-14 2024-10-17 Beijing Double-Crane Runchuang Technology Co., Ltd. Azacyclo-carbonyl-fused ring derivatives and use thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0901786T3 (da) 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
BR0207658A (pt) 2001-02-28 2005-10-25 Merck & Co Inc Métodos para o tratamento ou a prevenção de distúrbios, doenças ou condições responsivas à ativação do receptor de melanocortina-4, de obesidade, de diabetes melito, de disfunção sexual masculina ou feminina, e de disfunção erétil em um mamìfero que disto necessita, e, composição farmacêutica
EA200400980A1 (ru) 2002-02-27 2005-02-24 Пфайзер Продактс Инк. Ингибиторы асс
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
WO2004092179A1 (ja) 2003-04-14 2004-10-28 Nippon Soda Co. Ltd. スピロ誘導体、製造法および抗酸化薬
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
PL1753748T3 (pl) 2004-05-12 2010-01-29 Pfizer Prod Inc Pochodne proliny i ich zastosowanie jako inhibitorów peptydazy dipeptylowej IV
WO2005113069A2 (en) 2004-05-14 2005-12-01 Research Development Foundation Use of circumin and analogues as inhibitors of acc2
GEP20094723B (en) 2004-05-25 2009-07-10 Pfizer Prod Inc Tetraazabenzo [e] azulene derivatives and analogs thereof
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
KR20080036041A (ko) 2005-07-19 2008-04-24 머크 앤드 캄파니 인코포레이티드 아세틸 조효소 카복실라제(ａｃｃ) 억제제로서의스피로크로마논 유도체
US20100160255A1 (en) 2005-07-29 2010-06-24 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
EP1951251B1 (en) 2005-11-18 2010-12-29 Merck Sharp & Dohme Corp. Spirohydantoin aryl cgrp receptor antagonists
CA2641766A1 (en) 2006-02-15 2007-08-23 Abbott Laboratories Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
NL2000581C2 (nl) 2006-04-20 2008-01-03 Pfizer Prod Inc Aangecondenseerde fenylamidoheterocyclische verbindingen.
EA200900613A1 (ru) 2006-11-29 2009-10-30 Пфайзер Продактс Инк. Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
US20100113418A1 (en) * 2007-02-20 2010-05-06 Takeda Pharmaceutical Company Limited Heterocyclic compound
KR101113387B1 (ko) 2007-04-12 2012-04-23 화이자 인코포레이티드 단백질 키나아제 ｃ의 억제제로서의 3-아미도-피롤로［3,4-ｃ］피라졸-5(1ｈ,4ｈ,6ｈ)카브알데하이드 유도체
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
JP2011521940A (ja) 2008-05-28 2011-07-28 ファイザー・インク ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
CA2724774C (en) * 2008-05-28 2013-06-25 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
US8524730B2 (en) * 2008-07-04 2013-09-03 Msd K.K. Spirochromanone carboxylic acids
AU2009271634A1 (en) 2008-07-14 2010-01-21 Cropsolution, Inc. Modulators of acetyl-coenzyme a carboxylase and methods of use thereof
CA2729581A1 (en) 2008-07-29 2010-02-04 Pfizer Inc. Fluorinated heteroaryls
MY155418A (en) 2008-08-28 2015-10-15 Pfizer Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
TW201038580A (en) 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
CA2754685A1 (en) 2009-03-11 2010-09-16 Pfizer Inc. Substituted indazole amides
EP2406253B1 (en) 2009-03-11 2013-07-03 Pfizer Inc. Benzofuranyl derivatives used as glucokinase inhibitors
WO2010106457A2 (en) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
EP2427450A1 (en) 2009-05-08 2012-03-14 Pfizer Inc. Gpr 119 modulators
US20120052130A1 (en) 2009-05-08 2012-03-01 Pfizer Inc. Gpr 119 modulators
GEP20135907B (en) 2009-06-05 2013-08-12 Pfizer L-(piperidin-4-yl)-pyrazole derivatives as gpr 119 modulators
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof
CA2778316A1 (en) * 2009-11-10 2011-05-19 Pfizer Inc. N-2 pyrazolospiroketone acetyl-coa carboxylase inhibitors
PT2499139E (pt) * 2009-11-10 2014-02-10 Pfizer Inibidores de n1-pirazolospirocetona acetil-coa carboxilase
ES2602111T3 (es) * 2010-09-30 2017-02-17 Pfizer Inc Inhibidores de acetil-CoA carboxilasas de N1-pirazoloespirocetona

Also Published As

Publication number Publication date
ECSP13013038A (es) 2014-01-31
GT201300258A (es) 2015-06-02
WO2012143813A1 (en) 2012-10-26
DK2699576T3 (en) 2016-02-15
TWI464171B (zh) 2014-12-11
CN106117205A (zh) 2016-11-16
KR101567659B1 (ko) 2015-11-09
EP2699576A1 (en) 2014-02-26
CR20130464A (es) 2013-10-16
RS54526B1 (en) 2016-06-30
PT2699576E (pt) 2016-03-09
ES2561452T3 (es) 2016-02-26
PE20141187A1 (es) 2014-09-18
EA201391288A1 (ru) 2014-04-30
HRP20151397T1 (hr) 2016-01-15
US20120270893A1 (en) 2012-10-25
MY162167A (en) 2017-05-31
TW201305162A (zh) 2013-02-01
UA107753C2 (xx) 2015-02-10
CA2831380A1 (en) 2012-10-26
JP2014515755A (ja) 2014-07-03
HUE028602T2 (hu) 2016-12-28
TN2013000393A1 (fr) 2015-01-20
IL228949A0 (en) 2013-12-31
US20150112068A1 (en) 2015-04-23
CU20130126A7 (es) 2014-01-29
ME02312B (me) 2016-06-20
MX2013012313A (es) 2014-01-31
NI201300111A (es) 2014-02-12
US20140323730A1 (en) 2014-10-30
AU2012245996A1 (en) 2013-10-03
GEP20166474B (en) 2016-05-10
AP3499A (en) 2015-12-31
CN106117205B (zh) 2018-09-21
AR086198A1 (es) 2013-11-27
CU24164B1 (es) 2016-03-31
DOP2013000243A (es) 2013-12-31
EP2699576B1 (en) 2015-12-09
KR20140015511A (ko) 2014-02-06
CY1117122T1 (el) 2017-04-05
PL2699576T3 (pl) 2016-05-31
AP2013007129A0 (en) 2013-09-30
IL228949A (en) 2016-11-30
US8802688B2 (en) 2014-08-12
MX348860B (es) 2017-06-30
CA2831380C (en) 2016-04-05
EA022375B1 (ru) 2015-12-30
SI2699576T1 (sl) 2016-02-29
JP5657174B2 (ja) 2015-01-21
MA35061B1 (fr) 2014-04-03
CL2013002794A1 (es) 2013-12-27
US20150336958A1 (en) 2015-11-26
SG194142A1 (en) 2013-11-29
NZ616156A (en) 2014-08-29
CO6801757A2 (es) 2013-11-29
CN103492388A (zh) 2014-01-01
AU2012245996B2 (en) 2016-09-01

Similar Documents

Publication Publication Date Title
UY34027A (es) Inhibidores sustituidos de acetil-coa carboxilasa.
UY34145A (es) Compuestos inhibidores de metaloenzimas
UY34146A (es) Compuestos inhibidores de metaloenzimas
UY33958A (es) Inhibidores de la glucosilceramida sintasa
UY34559A (es) Inhibidores de bromodominios
UY34456A (es) Anticuerpos anti-il-36r
UY34156A (es) Compuestos inhibidores de metaloenzimas
UY33925A (es) Inhibidores tricíclicos de quinasas
UY34817A (es) Tienopirimidinas
UY34550A (es) Bencilpirazoles sustituidos
UY34503A (es) ?sal de bromhidrato de pridopidina?
UY34177A (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
UY33930A (es) Inhibidores novedosos de quinasas
UY34374A (es) Benzilindazoles sustituidos
UY34654A (es) Inhibidores de la beta-secretasa
UY4175Q (es) Reloj pulsera
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
UY34206A (es) Anticuerpo monoclonal de interleucina-31
UY34472A (es) Derivados modificados de 4-fenil-piridina
UY34034A (es) Triazolopiridinas
UY34006A (es) Imidazopiridazinas
UY34666A (es) Inhibidores de quinasa a base de ariléter
UY4281Q (es) Juguera
BR112014003027A2 (pt) formulação herbicida melhorada
UY34442A (es) 2-tiopirimidinonas.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201019